Wednesday, July 8, 2026

biotech · Chronic Hepatitis b · Hepatitis B, Chronic · ABUS

Arbutus Biopharma

Arbutus Biopharma clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

701 Veterans Circle, Warminster, Pennsylvania 18974, US HQ
49 Employees
Public company Type
ABUS · NYSE Ticker
Company details
Status
Public
HQ
701 Veterans Circle, Warminster, Pennsylvania 18974, US
Employees
49
Programs
13
Drugs
7
Patents
56
Intelligence · Clinical Programs

Arbutus Biopharma projects

6 ClinicalTrials.gov programs sponsored by Arbutus Biopharma.

Arbutus Biopharma has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AB-101

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 1 small molecule completed

    1 trial
  2. AB-101-001

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial
  3. AB-836

    Arbutus Biopharma Corp

    Chronic Hepatitis

    phase 1 small molecule terminated

    1 trial
  4. PRO-040201

    Arbutus Biopharma Corp

    Hypercholesterolemia

    phase 1 small molecule terminated

    1 trial
  5. TKM-100201

    Arbutus Biopharma Corp

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial
  6. TKM-100802 for Injection

    Arbutus Biopharma Corp

    Ebola Virus Infection

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Arbutus Biopharma have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.